Amgen Inc. Stock

Equities

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2024-06-14 EDT 5-day change 1st Jan Change
298.6 USD +0.04% Intraday chart for Amgen Inc. -2.10% +3.68%
Sales 2024 * 33B 45.32B Sales 2025 * 33.97B 46.65B Capitalization 160B 220B
Net income 2024 * 4.11B 5.64B Net income 2025 * 6.21B 8.53B EV / Sales 2024 * 6.33 x
Net Debt 2024 * 48.6B 66.75B Net Debt 2025 * 43.61B 59.9B EV / Sales 2025 * 6 x
P/E ratio 2024 *
37.6 x
P/E ratio 2025 *
24.2 x
Employees 26,700
Yield 2024 *
3.09%
Yield 2025 *
3.33%
Free-Float 99.75%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.04%
1 week-2.10%
Current month-2.36%
1 month-6.40%
3 months+11.06%
6 months+8.41%
Current year+3.68%
More quotes
1 week
295.30
Extreme 295.3
305.53
1 month
295.30
Extreme 295.3
316.67
Current year
260.68
Extreme 260.68
329.72
1 year
218.44
Extreme 218.44
329.72
3 years
198.64
Extreme 198.64
329.72
5 years
173.12
Extreme 173.12
329.72
10 years
114.93
Extreme 114.93
329.72
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 06-05-31
Director of Finance/CFO 65 19-10-22
Chief Tech/Sci/R&D Officer 52 12-17
Members of the board TitleAgeSince
Director/Board Member 67 17-02-02
Director/Board Member 68 16-10-13
Director/Board Member 69 02-12-31
More insiders
Date Price Change Volume
24-06-14 298.6 +0.04% 1,713,616
24-06-13 298.5 -0.86% 1,732,666
24-06-12 301.1 +0.13% 1,640,098
24-06-11 300.7 -1.32% 1,740,194
24-06-10 304.7 -0.10% 1,992,837

Delayed Quote Nasdaq, June 14, 2024 at 04:00 pm

More quotes
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
298.6 USD
Average target price
316.4 USD
Spread / Average Target
+5.97%
Consensus